LT3359185T - Priešnavikinė kompozicija - Google Patents

Priešnavikinė kompozicija

Info

Publication number
LT3359185T
LT3359185T LTEPPCT/FR2016/052598T LT16052598T LT3359185T LT 3359185 T LT3359185 T LT 3359185T LT 16052598 T LT16052598 T LT 16052598T LT 3359185 T LT3359185 T LT 3359185T
Authority
LT
Lithuania
Prior art keywords
cumor
composition
cumor composition
Prior art date
Application number
LTEPPCT/FR2016/052598T
Other languages
English (en)
Inventor
Jean-Marc Limacher
Original Assignee
Jean-Marc Limacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean-Marc Limacher filed Critical Jean-Marc Limacher
Publication of LT3359185T publication Critical patent/LT3359185T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
LTEPPCT/FR2016/052598T 2015-10-08 2016-10-07 Priešnavikinė kompozicija LT3359185T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1559589A FR3042121A1 (fr) 2015-10-08 2015-10-08 Composition anti-tumorale
FR1659450A FR3042122B1 (fr) 2015-10-08 2016-09-30 Composition anti-tumorale
PCT/FR2016/052598 WO2017060650A1 (fr) 2015-10-08 2016-10-07 Composition anti-tumorale

Publications (1)

Publication Number Publication Date
LT3359185T true LT3359185T (lt) 2022-06-27

Family

ID=55178130

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/FR2016/052598T LT3359185T (lt) 2015-10-08 2016-10-07 Priešnavikinė kompozicija

Country Status (14)

Country Link
US (2) US20180296653A1 (lt)
EP (1) EP3359185B1 (lt)
JP (1) JP7211815B2 (lt)
KR (1) KR20180059547A (lt)
CN (1) CN108348587A (lt)
CA (1) CA2999948C (lt)
DK (1) DK3359185T3 (lt)
ES (1) ES2919134T3 (lt)
FR (2) FR3042121A1 (lt)
HK (1) HK1253315A1 (lt)
IL (1) IL258430B (lt)
LT (1) LT3359185T (lt)
RU (1) RU2728748C2 (lt)
WO (1) WO2017060650A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
CA3182994A1 (en) * 2020-06-30 2022-01-06 Bo YING Lipid compounds and lipid nanoparticle compositions
CN116676324B (zh) * 2023-07-28 2023-10-27 四川大学华西医院 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US6869793B2 (en) 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
WO1999015692A2 (en) 1997-09-23 1999-04-01 Bavarian Nordic Research Institute A/S Dengue virus antigens and treatment of dengue fever
MXPA02008873A (es) 2000-03-14 2003-02-10 Anton Mayr Cepa alterada del virus de vaccinia ankara modificado (mva).
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
JP4500049B2 (ja) 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
NZ533302A (en) 2001-12-10 2005-11-25 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions containing a disaaccharide and a pharmaceutically acceptable polymer i.e. dextran or polyvinylpyrrolidon (PVP)
EP1407006B9 (en) 2001-12-20 2006-10-18 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
SG173216A1 (en) 2002-04-19 2011-08-29 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
BR0310020A (pt) 2002-05-16 2005-02-15 Bavarian Nordic As Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
SI1506223T1 (sl) 2002-05-16 2006-04-30 Bavarian Nordic As Fuzijski protein HIV regulatornih/akcesorskih proteinov
KR101138067B1 (ko) 2002-05-16 2012-04-24 버베리안 노딕 에이/에스 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
US7785778B2 (en) 2002-11-25 2010-08-31 University Of Copenhagen Porcine polymorphisms and methods for detecting them
KR20050083839A (ko) 2002-11-25 2005-08-26 버베리안 노딕 에이/에스 두개 이상의 우두 ａｔｉ 프로모터를 포함하는 재조합폭스바이러스
EP1615661A2 (en) * 2003-04-15 2006-01-18 Sanofi Pasteur Limited Tumor antigens bfa5 for prevention and/or treatment of cancer
ATE471383T1 (de) 2003-11-24 2010-07-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara
DK1855720T4 (da) 2005-02-23 2023-07-24 Bavarian Nordic As Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer
US20100011451A1 (en) 2006-09-08 2010-01-14 Paul Chaplin Phenotypic and genotypic differences of mva strains
NZ575388A (en) 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
AU2008243343C9 (en) 2007-04-27 2015-03-19 Bavarian Nordic A/S Induction of dendritic cell development with Macrophage-Colony Stimulating Factor (M-CSF)
CA2676149C (en) 2007-05-14 2016-06-21 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US7867483B2 (en) 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
WO2009143565A1 (en) * 2008-05-26 2009-12-03 Tyrian Diagnostics Limited Method of diagnosis of infection by mycobacteria and reagents therefor
EP2303322A1 (en) 2008-06-20 2011-04-06 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
AU2009317517B2 (en) 2008-11-21 2014-12-04 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
JP2012509678A (ja) 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
SG178909A1 (en) 2009-10-08 2012-04-27 Bavarian Nordic As Generation of a broad t-cell response in humans against hiv
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva
AU2011281982B2 (en) 2010-07-20 2015-12-17 Bavarian Nordic A/S Method for harvesting expression products
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
AU2011325459B2 (en) 2010-11-05 2016-11-10 Bavarian Nordic A/S Modulation of immune responses by the poxviral K4 protein
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
WO2013189611A1 (en) 2012-06-22 2013-12-27 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
BR112015002131B1 (pt) 2012-08-01 2022-11-01 Bavarian Nordic A/S Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
CA2888367A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
BR112015009320A2 (pt) 2012-10-28 2017-10-17 Bavarian Nordic As promotor pr13.5 para respostas de células t e anticorpo robustas
US9402888B2 (en) * 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
CN105744950A (zh) * 2013-11-05 2016-07-06 巴法里安诺迪克有限公司 用于使用表达肿瘤抗原的痘病毒和免疫检查点抑制剂的拮抗剂和/或激动剂治疗癌症的组合疗法
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
KR20180006916A (ko) * 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도

Also Published As

Publication number Publication date
EP3359185A1 (fr) 2018-08-15
RU2018115534A3 (lt) 2020-02-26
KR20180059547A (ko) 2018-06-04
US20210138053A1 (en) 2021-05-13
DK3359185T3 (da) 2022-07-04
EP3359185B1 (fr) 2022-04-06
CA2999948C (fr) 2024-04-23
FR3042122A1 (fr) 2017-04-14
IL258430A (en) 2018-06-28
CN108348587A (zh) 2018-07-31
CA2999948A1 (fr) 2017-04-13
FR3042121A1 (fr) 2017-04-14
JP2018531238A (ja) 2018-10-25
RU2018115534A (ru) 2019-11-08
RU2728748C2 (ru) 2020-07-31
ES2919134T3 (es) 2022-07-22
US20180296653A1 (en) 2018-10-18
FR3042122B1 (fr) 2020-01-17
HK1253315A1 (zh) 2019-06-14
JP7211815B2 (ja) 2023-01-24
IL258430B (en) 2022-03-01
WO2017060650A1 (fr) 2017-04-13

Similar Documents

Publication Publication Date Title
EP3493800A4 (en) CANNABIS
DK3361870T3 (da) Fungicidsammensætninger
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
DK3416996T3 (da) Hærdelig sammensætning
DK3130649T3 (da) Haloolefin-baseret sammensætning
DK3542812T3 (da) Glycopeptidsammensætninger
FR3024363B1 (fr) Composition thermogelifiable
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3528902T3 (da) Ringegelsammensætning
EP3430073A4 (en) COMPOSITION BASED ON A POLYARYLETHERKETONE COMPOSITION
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
DK3322295T3 (da) Sammensætning
CL2017000639A1 (es) Composición
EP3480228A4 (en) COMPOSITION
DK3331498T3 (da) Nasalsammensætning
DK3316857T3 (da) Multifasiske sammensætninger
EP3556804A4 (en) COMPOSITION
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija
EP3369418A4 (en) COMPOSITION
EP3236746C0 (en) COMPOSITION
DE102015206660A8 (de) Plattenaufteilanlage
EP3443034C0 (en) COMPOSITION